KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: KRAS is one of commonly mutated genetic “drivers” in non-small cell lung cancers (NSCLCs). Recent studies indicate that patients with KRAS-mutated tumors do not benefit from adjuvant chemotherapy, so there is now a focus on targeting KRAS-mutated NSCLCs. A feasible mutation detection method is required in order to accurately test for KRAS status. Methods: We compared direct Sanger sequencing and the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method in 134 NSCLCs and explored associations with clinicopathological factors. Next-generation sequencing (NGS) was used to validate the results of discordant cases. To increase the resolution of low-level somatic mutant molecules, PNA-mediated PCR clamping was used for mutant enrichment prior to NGS. Results: Twenty-one (15.7%) cases were found to have the KRAS mutations using direct sequencing, with two additional cases by the PNA-mediated PCR clamping method. The frequencies of KRAS mutant alleles were 2% and 4%, respectively, using conventional NGS, increasing up to 90% and 89%, using mutant-enriched NGS. The KRAS mutation occurs more frequently in the tumors of smokers (p=.012) and in stage IV tumors (p=.032). Conclusions: Direct sequencing can accurately detect mutations, but, it is not always possible to obtain a tumor sample with sufficient volume. The PNA-mediated PCR clamping can rapidly provide results with sufficient sensitivity.
Abstract
Background: KRAS is one of commonly mutated genetic “drivers” in non-small cell lung cancers (NSCLCs). Recent studies indicate that patients with KRAS-mutated tumors do not benefit from adjuvant chemotherapy, so there is now a focus on targeting KRAS-mutated NSCLCs. A feasible mutation detection method is required in order to accurately test for KRAS status. Methods: We compared direct Sanger sequencing and the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method in 134 NSCLCs and explored associations with clinicopathological factors. Next-generation sequencing (NGS) was used to validate the results of discordant cases. To increase the resolution of low-level somatic mutant molecules, PNA-mediated PCR clamping was used for mutant enrichment prior to NGS. Results: Twenty-one (15.7%) cases were found to have the KRAS mutations using direct sequencing, with two additional cases by the PNA-mediated PCR clamping method. The frequencies of KRAS mutant alleles were 2% and 4%, respectively, using conventional NGS, increasing up to 90% and 89%, using mutant-enriched NGS. The KRAS mutation occurs more frequently in the tumors of smokers (p=.012) and in stage IV tumors (p=.032). Conclusions: Direct sequencing can accurately detect mutations, but, it is not always possible to obtain a tumor sample with sufficient volume. The PNA-mediated PCR clamping can rapidly provide results with sufficient sensitivity.
참고문헌 (30)
- Riely GJ, "KRAS mutations in non-small cell lung cancer", Proc Am Thorac Soc, 6, pp.201~205 (2009)
- Forbes S, "Cosmic 2005", Br J Cancer, 94, pp.318~322 (2006)
- Herbst RS, "TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer", J Clin Oncol, 23, pp.5892~5899 (2005)
- Pao W, "KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib", PLoS Med, 2, pp.e17~ (2005)
- Kim ES, "The BATTLE trial: personalizing therapy for lung cancer", Cancer Discov, 1, pp.44~53 (2011)
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
- Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
- Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", Arch Pathol Lab Med, 137, pp.828~860 (2013)
- Thiede C, "Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping", Nucleic Acids Res, 24, pp.983~984 (1996)
- Nielsen PE, "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide", Science, 254, pp.1497~1500 (1991)
- Beau-Faller M, "Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping", Br J Cancer, 100, pp.985~992 (2009)
- 권미정, "Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue", PATHOLOGY RESEARCH AND PRACTICE, 207(12), pp.762~768 (2011), ELSEVIER GMBH
- Araki T, "Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods", J Mol Diagn, 12, pp.118~124 (2010)
- 정동준, "Detection of BRAFV600E Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing", Journal of Pathology and Translational Medicine, 46(1), pp.61~67 (2012), 대한병리학회
- 이현주, "Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment", Journal of Pathology and Translational Medicine, 47(1), pp.52~60 (2013), 대한병리학회
- Le Calvez F, "TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers", Cancer Res, 65, pp.5076~5083 (2005)
- Cadranel J, "Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project. part 2)", J Thorac Oncol, 7, pp.1490~1502 (2012)
- Guan JL, "KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy", Ann Surg Oncol, 20, pp.1381~1388 (2013)
- Kim HR, "Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement", CANCER, 118(3), pp.729~739 (2012), JOHN WILEY & SONS INC
- Kosaka T, "Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma", J Thorac Oncol, 4, pp.22~29 (2009)
- Ragusa M, "Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients", Am J Clin Oncol (2013)[DOI]
- Sonobe M, "Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas", Ann Surg Oncol, 19(Suppl 3), pp.S347~S354 (2012)
- Mascaux C, "The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis", Br J Cancer, 92, pp.131~139 (2005)
- Marchetti A, "Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones", Neoplasia, 11, pp.1084~1092 (2009)
- Sun JM, "Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer", PLoS One, 8, pp.e64816~ (2013)
- Johnson ML, "Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas", Cancer, 119, pp.356~362 (2013)
- Kerner GS, "Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome", PLoS One, 8, pp.e70346~ (2013)
- Lim EH, "Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)", J Thorac Oncol, 4, pp.12~21 (2009)
- Liu HP, "Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan", J Thorac Oncol, 5, pp.1175~1184 (2010)
- Scoccianti C, "Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort", Eur Respir J, 40, pp.177~184 (2012)